Tag: genetic disease

May 8, 2018

Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate...
April 23, 2018

CTD Holdings Closes $2.00 Million Private Placement

CTD Holdings (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical...
February 15, 2018

Agios Receives FDA Priority Review for New Drug Application: How are Gene Therapy Drug Approvals Impacting Stocks?

INN is taking a look at what other companies have received FDA approval for gene therapy drugs and how the...
January 24, 2018

FDA Grants Approval to Shire for Technology Transfer of CINRYZE® Drug Product Manufacturing Process to Vienna

Shire (NASDAQ:SHPG) the global biotechnology leader in rare diseases, announced today that the U.S. Food and Drug Administration has granted...
January 19, 2018

Arimoclomol for NPC receives Rare Pediatric Disease Designation

Orphazyme A/S, a Danish biotech company (ORPHA:CO), with a late-stage, orphan-drug pipeline, today announced that arimoclomol has been granted rare...
September 28, 2017

CTD Holdings Enrolls First Patient in Phase I Clinical Trial

CTD Holdings announced it enrolled the first patient in their phase 1 clinical trial evaluating the intravenous administration of Trappsol...
February 16, 2017

CTD Holdings Presents Compassionate Use Data on Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C and Provides Update on Progress of U.S. and EU Clinical Trials at 13th Annual WORLDSymposium

CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, presented updated...